Sorafenib, a targeted anticancer drug for the treatment of inoperable and distant metastatic HCC and advanced clear cell renal cell carcinoma (ccRCC), is recognized as a substrate of OATP1B1 and OATP1B3 [86, 87]. Here, SLCO1B3 is linked to hepatocellular carcinoma.